Chrysin - Nexavar (Sorafenib) Interaction

Interaction Details

Sorafenib is classified as belonging to the following category: Anticoagulant/Antiplatelet Drugs

In vitro evidence suggests that chrysin might inhibit platelet aggregation. Theoretically, taking chrysin with other antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding in some patients. Some anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Galijatovic A, Otake Y, Walle UK, Walle T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 1999;29:1241-56.
• O'Leary, K. A., de Pascual-Tereasa, S., Needs, P. W., Bao, Y. P., O'Brien, N. M., and Williamson, G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat.Res 7-13-2004;551(1-2):245-254.
• Woodman, O. L. and Chan, E. C. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 2004;31(11):786-790.
• Landolfi, R., Mower, R. L., and Steiner, M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol 5-1-1984;33(9):1525-1530.
• Liu G, Xie W, He AD, et al. Antiplatelet activity of chrysin via inhibiting platelet aIIbß3-mediated signaling pathway. Mol Nutr Food Res 2016;60(9):1984-93.

Interaction Details

Sorafenib is classified as belonging to the following category: Glucuronidated Drugs

There is some preliminary evidence that chrysin might induce UDP-glucuronosyltransferase 1A1 (UGT1A1) . Theoretically, chrysin might increase the clearance of drugs that are UGT1A1 substrates, such as acetaminophen (Tylenol), estrogens (Estrace, Premarin, others) and oral contraceptives, entacapone (Comtan), irinotecan (Camptosar), and others.

Interaction Rating

Likelihood of Occurrence

Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.

References

• Galijatovic A, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res 2000;17:21-6.
• Walle T, Otake Y, Galijatovic A, et al. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos 2000;28:1077-82.
• Galijatovic A, Otake Y, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res 2001;18:374-9.

Sorafenib Overview

• Sorafenib is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). Sorafenib is also used to treat hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery and a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

Chrysin - More Interactions

Chrysin interacts with 350 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.